作者
LG Roth, T O'Donohue, Z Chen, N Bartlett, W Martin‐Doyle, MJ Barth, K Davies, B Christian, C Casulo, J Godfrey, MJ Oberley, S Alexander, S Weitzman, B Appel, J Svoboda, Z Afify, M Pauly, H Dave, R Gardner, DM Stephens, WA Zeitler, C Forlenza, J Levine, ME Williams, CM Bollard, JP Leonard
发表日期
2017/6
期刊
Hematological Oncology
卷号
35
页码范围
61-62
简介
Methods: 156 patients with PMBCL treated with DA-EPOCH-R across 24 academic medical centers were assessed, including 38 children and 118 adults. All patients received at least one cycle of DA-EPOCH-R. Radiation therapy was administered at the completion of DA-EPOCH-R in 14.7% of patients.
Results: With median follow-up of 22.6 months (range 2.7-101.0 months), the estimated 3-year EFS is 85.9%(95% CI 80.3-91.5) and OS is 95.4%(95% CI 91.8-99.0). Outcomes were similar in pediatric and adult patients. Pediatric patients were more likely to present with bulky mediastinal disease and were more likely to be escalated to at least dose level 4. Thrombotic complications were reported in 28.2% of patients and were more common in pediatric patients (45.9% vs. 22.9%, p= 0.011). The sites of thromboses included: upper extremity (n= 22), internal jugular vein or superior vena cava (n= 10), intracardiac (n …
学术搜索中的文章
LG Roth, T O'Donohue, Z Chen, N Bartlett… - Hematological Oncology, 2017